San Diego-based Leo Lens Pharma recently announced the appointment of Dan Myers as the company’s new Chief Executive Officer.
Prior to joining Leo Lens, Myers was the Co-Founder and Chief Executive Officer of Alimera Sciences. He continues to serve as the Chairman of the Board of Directors of Alimera.
Before founding Alimera, Myers was a founding employee of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics) and served as its President from 1997 to 2003.
Myers has over 35 years of ophthalmic pharmaceutical experience, including over 21 years in the role of President or Chief executive officer.
“Our founding team is thrilled that Dan is joining Leo Lens,” commented Praful Doshi, Founder and CTO. “His proven track record of developing and commercializing novel ophthalmic pharmaceutical products and fundraising in the private and public markets will allow us to expedite our plan to bring our unique glaucoma therapy to patients and eye care professionals. I could think of no one better to help us protect sight for millions of patients suffering from the effects of glaucoma.”
“I’m excited and honored to be joining Leo Lens at such a pivotal time in its progression,” added Dan Myers, the Company’s new CEO. “Our enterprise is poised to address the significant unmet need in glaucoma treatment by successfully advancing the development of our proprietary MediPrint™ process. We are currently building a proven pharmaceutical and ophthalmic management team to execute on this strategy and to create what I believe will be a very successful company.”
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.